256 related articles for article (PubMed ID: 19152426)
21. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
[TBL] [Abstract][Full Text] [Related]
22. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
23. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria.
Xu X; Lu D; Ling Q; Wei X; Wu J; Zhou L; Yan S; Wu L; Geng L; Ke Q; Gao F; Tu Z; Wang W; Zhang M; Shen Y; Xie H; Jiang W; Wang H; Zheng S
Gut; 2016 Jun; 65(6):1035-41. PubMed ID: 25804634
[TBL] [Abstract][Full Text] [Related]
24. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
[TBL] [Abstract][Full Text] [Related]
26. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.
Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Kim IH; Yi NJ; Lee KU
Surgery; 2007 May; 141(5):598-609. PubMed ID: 17462459
[TBL] [Abstract][Full Text] [Related]
27. Super-selection of a subgroup of hepatocellular carcinoma patients at minimal risk of recurrence for liver transplantation.
Hwang S; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Park GC; Yu YD; Park PJ; Choi YI; Kim KW; Lim YS; Lee HC; Yu ES; Lee SG
J Gastrointest Surg; 2011 Jun; 15(6):971-81. PubMed ID: 21547706
[TBL] [Abstract][Full Text] [Related]
28. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
[TBL] [Abstract][Full Text] [Related]
29. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
Vitale A; Farinati F; Burra P; Trevisani F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Chiaramonte M; Spolverato G; Cillo U;
Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
[TBL] [Abstract][Full Text] [Related]
30. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
Lee KW; Yi NJ; Suh KS
Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
[TBL] [Abstract][Full Text] [Related]
31. Downstaging prior to liver transplantation for hepatocellular carcinoma: advisable but at the price of an increased risk of cancer recurrence - a retrospective study.
Toso C; Meeberg G; Andres A; Shore C; Saunders C; Bigam DL; Shapiro AMJ; Compagnon P; Berney T; Majno P; Kneteman N
Transpl Int; 2019 Feb; 32(2):163-172. PubMed ID: 30152891
[TBL] [Abstract][Full Text] [Related]
32. Addition of alfa fetoprotein to traditional criteria for hepatocellular carcinoma improves selection accuracy in liver transplantation.
Sternby Eilard M; Holmberg E; Naredi P; Söderdahl G; Rizell M
Scand J Gastroenterol; 2018 Aug; 53(8):976-983. PubMed ID: 30169974
[TBL] [Abstract][Full Text] [Related]
33. Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria.
Kashkoush S; El Moghazy W; Kawahara T; Gala-Lopez B; Toso C; Kneteman NM
Clin Transplant; 2014 Jun; 28(6):728-36. PubMed ID: 24708263
[TBL] [Abstract][Full Text] [Related]
34. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.
Bhatti ABH; Qureshi AI; Tahir R; Dar FS; Khan NY; Zia HH; Riyaz S; Rana A
BMC Cancer; 2020 Aug; 20(1):754. PubMed ID: 32787864
[TBL] [Abstract][Full Text] [Related]
35. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.
Duffy JP; Vardanian A; Benjamin E; Watson M; Farmer DG; Ghobrial RM; Lipshutz G; Yersiz H; Lu DS; Lassman C; Tong MJ; Hiatt JR; Busuttil RW
Ann Surg; 2007 Sep; 246(3):502-9; discussion 509-11. PubMed ID: 17717454
[TBL] [Abstract][Full Text] [Related]
36. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma.
Ho CM; Wu CY; Lee PH; Lai HS; Ho MC; Wu YM; Hu RH
Ann Surg Oncol; 2013 Aug; 20(8):2526-33. PubMed ID: 23504121
[TBL] [Abstract][Full Text] [Related]
38. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
[TBL] [Abstract][Full Text] [Related]
39. Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation.
Teng F; Wang GH; Tao YF; Guo WY; Wang ZX; Ding GS; Shi XM; Fu ZR
World J Gastroenterol; 2014 Aug; 20(31):10900-7. PubMed ID: 25152592
[TBL] [Abstract][Full Text] [Related]
40. Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria.
Lee YH; Hsia CY; Hsu CY; Huang YH; Lin HC; Huo TI
World J Surg; 2013 Jun; 37(6):1348-55. PubMed ID: 23467925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
